Clinical prodromes of neurodegeneration in Anderson-Fabry disease

Neurology

Volumn 84, Issue 14, 2015, Pages 1454-1464

  Löhle, Matthias ^a,c   Hughes, Derralynn ^b   Milligan, Alan ^b   Richfield, Linda ^b   Reichmann, Heinz ^c   Mehta, Atul ^b   Schapira, Anthony H V ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ANDERSON FABRY DISEASE; ARTICLE; CLINICAL FEATURE; COGNITION; CONTROLLED STUDY; DAYTIME SOMNOLENCE; DEPRESSION; FABRY DISEASE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOTOR PERFORMANCE; NERVE DEGENERATION; PAIN; PARASOMNIA; PREVALENCE; PRIORITY JOURNAL; PRODROMAL SYMPTOM; QUALITY OF LIFE; SMELLING; ADOLESCENT; AGED; COMPLICATION; CROSS-SECTIONAL STUDY; NEURODEGENERATIVE DISEASES; PATHOPHYSIOLOGY; PHENOTYPE; PROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CROSS-SECTIONAL STUDIES; FABRY DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEURODEGENERATIVE DISEASES; PHENOTYPE; PREVALENCE; PRODROMAL SYMPTOMS; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84926650418     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000001450     Document Type: Article

References (40)

1. Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L. Enzymatic defect in Fabry's disease: ceramidetrihexosidase deficiency. N Engl J Med 1967;276:1163-1167
2. Dutsch M, Marthol H, Stemper B, Brys M, Haendl T, Hilz MJ. Small fiber dysfunction predominates in Fabry neuropathy. J Clin Neurophysiol 2002;19:575-586
3. Mitsias P, Levine SR. Cerebrovascular complications of Fabry's disease. Ann Neurol 1996;40:8-17
4. deVeber GA, Schwarting GA, Kolodny EH, Kowall NW. Fabry disease: immunocytochemical characterization of neuronal involvement. Ann Neurol 1992;31:409-415
5. Kaye EM, Kolodny EH, Logigian EL, Ullman MD. Nervous system involvement in Fabry's disease: clinicopathological and biochemical correlation. Ann Neurol 1988;23: 505-509
6. NelsonMP, TseTE, O'Quinn DB, et al. Autophagy-lysosome pathway associated neuropathology and axonal degeneration in the brains of alpha-galactosidase A-deficient mice. Acta Neuropathol Commun 2014;2:20
7. Sidransky E, Nalls MA, Aasly JO, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med 2009;361:1651-1661
8. Borsini W, Giuliacci G, Torricelli F, Pelo E, Martinelli F, Scordo MR. Anderson-Fabry disease with cerebrovascular complications in two Italian families. Neurol Sci 2002;23: 49-53
9. Buechner S, De Cristofaro MT, Ramat S, Borsini W. Parkinsonism and Anderson Fabry's disease: a case report. Mov Disord 2006;21:103-107
10. McNeill A, Duran R, Proukakis C, et al. Hyposmia and cognitive impairment in Gaucher disease patients and carriers. Mov Disord 2012;27:526-532
11. Whybra C, Kampmann C, Krummenauer F, et al. The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clin Genet 2004;65:299-307
12. Podsiadlo D, Richardson S. The timed "Up & Go": a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc 1991;39:142-148
13. Desrosiers J, Hebert R, Bravo G, Dutil E. The Purdue Pegboard Test: normative data for people aged 60 and over. Disabil Rehabil 1995;17:217-224
14. Nutt JG, Lea ES, Van Houten L, Schuff RA, Sexton GJ. Determinants of tapping speed in normal control subjects and subjects with Parkinson's disease: differing effects of brief and continued practice. Mov Disord 2000;15:843-849
15. Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008;23: 2129-2170
16. Goldstein LB, Samsa GP. Reliability of the National Institutes of Health Stroke Scale: extension to non-neurologists in the context of a clinical trial. Stroke 1997;28:307-310
17. Folstein MF, Robins LN, Helzer JE. The Mini-Mental State Examination. Arch Gen Psychiatry 1983;40:812
18. Nasreddine ZS, PhillipsNA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005;53:695-699
19. Dalrymple-Alford JC, MacAskill MR, Nakas CT, et al. The MoCA: well-suited screen for cognitive impairment in Parkinson disease. Neurology 2010;75:1717-1725
20. Beck AT, Steer RA, Ball R, Ranieri W. Comparison of Beck Depression Inventories IA and II in psychiatric outpatients. J Pers Assess 1996;67:588-597
21. Silveira-Moriyama L, Petrie A, Williams DR, et al. The use of a color coded probability scale to interpret smell tests in suspected parkinsonism. Mov Disord 2009;24:1144-1153
22. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 1994;23: 129-138
23. Stiasny-Kolster K, Mayer G, Schafer S, Moller JC, Heinzel-Gutenbrunner M, Oertel WH. The REM sleep behavior disorder screening questionnaire: a new diagnostic instrument. Mov Disord 2007;22:2386-2393
24. Johns MW. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep 1991;14:540-545
25. Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 2011;20:1727-1736
26. McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): II: psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993;31:247-263
27. Gaenslen A, Wurster I, Brockmann K, et al. Prodromal features for Parkinson's disease: baseline data from the TREND study. Eur J Neurol 2014;21:766-772
28. Molano J, Boeve B, Ferman T, et al. Mild cognitive impairment associated with limbic and neocortical Lewy body disease: a clinicopathological study. Brain 2010;133:540-556
29. Sims K, Politei J, Banikazemi M, Lee P. Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry. Stroke 2009;40:788-794
30. Cole AL, Lee PJ, Hughes DA, Deegan PB, Waldek S, Lachmann RH. Depression in adults with Fabry disease: a common and under-diagnosed problem. J Inherit Metab Dis 2007;30:943-951
31. Uceyler N, Ganendiran S, Kramer D, Sommer C. Characterization of pain in Fabry disease. Clin J Pain 2014;30: 915-920
32. Duning T, Deppe M, Keller S, et al. Excessive daytime sleepiness is a common symptom in Fabry disease. Case Rep Neurol 2009;1:33-40
33. Low M, Nicholls K, Tubridy N, et al. Neurology of Fabry disease. Intern Med J 2007;37:436-447
34. Schermuly I, Muller MJ, Muller KM, et al. Neuropsychiatric symptoms and brain structural alterations in Fabry disease. Eur J Neurol 2011;18:347-353
35. Biegstraaten M, van Schaik IN, Wieling W, Wijburg FA, Hollak CE. Autonomic neuropathy in Fabry disease: a prospective study using the Autonomic Symptom Profile and cardiovascular autonomic function tests. BMC Neurol 2010;10:38
36. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211
37. Wilcox WR, Oliveira JP, Hopkin RJ, et al. Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol Genet Metab 2008;93:112-128
38. Germain DP, Echevarria L. Tissue-specific X chromosome inactivation studies as a decision-making criteria for enzyme replacement therapy in female heterozygotes for Fabry disease. Mol Genet Metab 2014;111:S45
39. Percy AK, Kaye EM. Does gender parity exist in Fabry disease?. Neurology 2005;65:508-509
40. Schapira AH, Gegg ME. Glucocerebrosidase in the pathogenesis and treatment of Parkinson disease. Proc Natl Acad Sci USA 2013;110:3214-3215